Cargando…

Heterogeneity‐based, multiple mechanisms in the resistance to osimertinib (AZD9291): A case report

Osimertinib is a novel, irreversible, mutant‐selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor targeting EGFR mutations and the EGFR T790 mutation. Here, we report a woman with EGFR‐mutated lung adenocarcinoma who, after 23‐month treatment with gefitinib, developed the EGFR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yutao, Hao, Xuezhi, Hu, Xingsheng, Li, Junling, Wang, Yan, Wang, Hongyu, Xing, Puyuan, Li, Weihua, Ying, Jianming, Han, Xiaohong, Shi, Yuankai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2018
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5879057/ https://www.ncbi.nlm.nih.gov/pubmed/29411527 http://dx.doi.org/10.1111/1759-7714.12596

Ejemplares similares

Osimertinib (AZD9291) increases radio-sensitivity in EGFR T790M non-small cell lung cancer
por: Wang, Nannan, et al.
Publicado: (2019)

AZD9291-induced Acute Interstitial Lung Disease
por: Nie, Ke-Ke, et al.
Publicado: (2016)

Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes
por: Mu, Yuxin, et al.
Publicado: (2020)

Osimertinib (AZD9291), a Mutant-Selective EGFR Inhibitor, Reverses ABCB1-Mediated Drug Resistance in Cancer Cells
por: Zhang, Xiao-Yu, et al.
Publicado: (2016)

Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line
por: Tang, Zheng-Hai, et al.
Publicado: (2016)

Co‐mutational assessment of circulating tumour DNA (ctDNA) during osimertinib treatment for T790M mutant lung cancer
por: Xing, Puyuan, et al.
Publicado: (2019)

Real-World Data Of Osimertinib In Patients With Pretreated Non-Small Cell Lung Cancer: A Retrospective Study
por: Mu, Yuxin, et al.
Publicado: (2019)

A case report of toxic epidermal necrolysis associated with AZD-9291
por: Wang, Jie, et al.
Publicado: (2018)

Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291)
por: Saad, Nibal, et al.
Publicado: (2017)

Exosomal long non-coding RNA MSTRG.292666.16 is associated with osimertinib (AZD9291) resistance in non-small cell lung cancer
por: Deng, Qinfang, et al.
Publicado: (2020)

AZD9291 inactivates the PRC2 complex to mediate tumor growth inhibition
por: Zhang, Kai-li, et al.
Publicado: (2019)

Transformation to small-cell carcinoma as an acquired resistance mechanism to AZD9291: A case report
por: Li, Lin, et al.
Publicado: (2017)

Advanced lung adenocarcinoma (LUAD) patient with EGFR mutations benefited from multiline combination targeted therapies after osimertinib (AZD9291) resistance: a case report
por: Chen, Jingyu, et al.
Publicado: (2022)

A prognostic model for platinum‐doublet as second‐line chemotherapy in advanced non‐small‐cell lung cancer patients
por: Mo, Hongnan, et al.
Publicado: (2016)

Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib
por: Mu, Yuxin, et al.
Publicado: (2019)

The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma
por: Liu, Xuejiao, et al.
Publicado: (2019)

Author Correction: AZD9291 inactivates the PRC2 complex to mediate tumor growth inhibition
por: Zhang, Kai-li, et al.
Publicado: (2020)

Non‐small cell lung cancer harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): A case report
por: Huang, Jing, et al.
Publicado: (2018)

Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model
por: Ku, Bo Mi, et al.
Publicado: (2018)

Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations
por: Li, Teng, et al.
Publicado: (2021)

Efficacy and safety of osimertinib plus anlotinib in advanced non‐small‐cell lung cancer patients after drug resistance
por: Wang, Mingzhao, et al.
Publicado: (2023)

Efficacy and safety profile of combining programmed cell death‐1 (PD‐1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non‐small cell lung cancer (NSCLC)
por: Xu, Ziyi, et al.
Publicado: (2021)

Gemcitabine combined with cisplatin as adjuvant chemotherapy for non‐small cell lung cancer: A retrospective analysis
por: Ma, Di, et al.
Publicado: (2017)

Efficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) in EGFR-Mutated Lung Adenocarcinoma: A Real-World Study in Chinese Patients
por: Xu, Ziyi, et al.
Publicado: (2022)

A Prospective Study of Apatinib in Patients with Extensive‐Stage Small Cell Lung Cancer After Failure of Two or More Lines of Chemotherapy
por: Liu, Yutao, et al.
Publicado: (2020)

Comprehensive Profiling of Gene Copy Number Alterations Predicts Patient Prognosis in Resected Stages I–III Lung Adenocarcinoma
por: Han, Xiaohong, et al.
Publicado: (2019)

Real world study of regimen containing bevacizumab as first‐line therapy in Chinese patients with advanced non‐small cell lung cancer
por: Xing, Puyuan, et al.
Publicado: (2018)

Real world study of the continuation of bevacizumab beyond disease progression after first‐line treatment containing bevacizumab in Chinese patients with advanced non‐small cell lung cancer
por: Xing, Puyuan, et al.
Publicado: (2018)

Heterogeneity in intracranial relapses after complete resection of lung adenocarcinoma: Distinct features of brain‐only relapse versus synchronous extracranial relapse
por: Xu, Fei, et al.
Publicado: (2023)

Comprehensive analysis of circular RNA profiling in AZD9291‐resistant non‐small cell lung cancer cell lines
por: Chen, Tianxiang, et al.
Publicado: (2019)

Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma
por: Wang, Shouzheng, et al.
Publicado: (2021)

AZD9291 Resistance Reversal Activity of a pH‐Sensitive Nanocarrier Dual‐Loaded with Chloroquine and FGFR1 Inhibitor in NSCLC
por: Gu, Yu, et al.
Publicado: (2020)

Investigation on the potential of circulating tumor DNA methylation patterns as prognostic biomarkers for lung squamous cell carcinoma
por: Liu, Yutao, et al.
Publicado: (2020)

DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild‐type NSCLC cells to AZD9291
por: Li, Yang‐ling, et al.
Publicado: (2019)

High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells
por: Nanjo, Shigeki, et al.
Publicado: (2015)

Positive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation after AZD9291 treatment: a case report
por: Wang, Junhui, et al.
Publicado: (2019)

Efficacy and safety of brigatinib in ALK-positive non-small cell lung cancer treatment: A systematic review and meta-analysis
por: Xing, Puyuan, et al.
Publicado: (2022)

Therapeutic cancer vaccine: phase I clinical tolerance study of Hu-rhEGF-rP64k/Mont in patients with newly diagnosed advanced non-small cell lung cancer
por: Xing, Puyuan, et al.
Publicado: (2018)

EGFR Exon 18 Mutations in Advanced Non-Small Cell Lung Cancer: A Real-World Study on Diverse Treatment Patterns and Clinical Outcomes
por: Xu, Haiyan, et al.
Publicado: (2021)

Clinical Characteristics and Treatment Outcomes of 65 Patients With BRAF-Mutated Non-small Cell Lung Cancer
por: Mu, Yuxin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_stggpd4k3r9euca5okdai4ag4c